These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18718191)

  • 1. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
    Alexandrescu DT; Dasanu CA; Farzanmehr H; Kauffman L
    Dermatol Online J; 2008 Jul; 14(7):7. PubMed ID: 18718191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pigmentary changes in a patient treated with imatinib.
    Balagula Y; Pulitzer MP; Maki RG; Myskowski PL
    J Drugs Dermatol; 2011 Sep; 10(9):1062-6. PubMed ID: 22052279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
    Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
    Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome.
    Campbell T; Felsten L; Moore J
    Arch Dermatol; 2009 Nov; 145(11):1313-6. PubMed ID: 19917964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
    Sawaki A; Yamao K
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
    Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
    Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
    Battistella M; Frémont G; Vignon-Pennamen MD; Gornet JM; Dubertret L; Viguier M
    Arch Dermatol; 2008 Oct; 144(10):1400-2. PubMed ID: 18936416
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
    Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe periorbital edema secondary to STI571 (Gleevec).
    Esmaeli B; Prieto VG; Butler CE; Kim SK; Ahmadi MA; Kantarjian HM; Talpaz M
    Cancer; 2002 Aug; 95(4):881-7. PubMed ID: 12209733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.